The system is available for patients whose mitral valves are not working properly due to severe mitral annular calcification.

Abbott's heart failure business. "By having more objective methods to accurately gauge heart failure progression and refer people to receive this life-saving therapy faster, healthcare experts ...

Abbott has launched a “first-of-its-kind” trial to identify advanced heart failure patients who could potentially benefit from early advanced therapy options, namely HeartMate 3 left ...

Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR) system.

It can cause uncomfortable symptoms like fatigue and in severe cases, can lead to heart failure. Abbott’s device, called the MitraClip, works by clipping the mitral valve’s leaflets together ...

Abbott announced the FDA approved its transcatheter mitral valve replacement system for patients with severe mitral annular ...

director of the Center for Valve & Structural Heart Disease for the Minneapolis Heart Institute at Abbott Northwestern Hospital. "Patients with MAC can be very difficult to operate on and many are ...

A new study finds a clear relationship between the frequency of cardiology consultations and improved survival in patients ...

is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational Coronary Intravascular Lithotripsy ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Abbott Laboratories is launching a new clinical trial ...

ABBOTT PARK, Ill., March 24, 2025 /PRNewswire/ -- Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary ...